

# 38th Annual J.P. Morgan Healthcare Conference

Galapagos



**Outlook for 2020:**  
Another exciting year  
for Galapagos

Thursday, 16 January 2020  
19:30 CET / 10:30 PST

with **Bart Filius**  
COO & CFO

Live streaming for investors available via link.

Great turnout for Bart Filius' presentation at the @jpmorgan Healthcare Conference, who set the scene for a newsflow rich 2020. Bottom line: this is only the beginning for \$glpg. We discover. We dare. We care! #JPM2020





## Looking forward to **a newsflow rich 2020**


**Topline data:**  
 filgotinib Ph3 UC  
 '1205 Ph2 IPF  
 '1690 Ph2 SSc  
 '1972 Ph2b OA  
 '3312 Ph2 UC

**Clinical trials:**  
 >80 GLPG clinical trials expected start filgotinib Ph3 AS  
 start '3970 PoC studies

**Potential launches:**  
 filgotinib in RA in US, Europe, Japan



## Filgotinib: potential for 5 launches in next 4 years




RA: rheumatoid arthritis CD: Crohn's disease UC: ulcerative colitis AS: ankylosing spondylitis PsA: psoriatic arthritis

**Galápagos**



## Building an IPF & fibrosis portfolio

Two toplines in H2 '20, ISABELA futility in Q1 '21




IPF: idiopathic pulmonary fibrosis, SSc: systemic sclerosis

Galapagos



## Toledo: robust activity in *in vivo* models



- Topline PoC in UC with '3312 in 2020
- Plan multiple PoC's with '3970 in patients in 2020

green: preclinical activity; orange: insufficient preclinical activity

Galapagos